DUBLIN, Ireland--(BUSINESS WIRE)--March 14, 2006--The Human Genome Sciences (NASDAQ:HGSI) Corporate Conference Call took place on 14-Mar-06 10:00am ET. The Co. reported on 03/14/06 that the 12-week data from the Phase 2b study reveals that Albuferon appears to be capable of meeting the base case target product profile at doses of 900-1,200 micrograms administered every 14 days. HGSI expects to continue to evaluate the possibility of administering Albuferon at higher doses on 14-day to as much as 28-day schedules.
